Advanced drug-delivery systems: mechanoresponsive nanoplatforms applicable in atherosclerosis management

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Benjamin E, Muntner P, Alonso A et al. Heart disease and stroke statistics-2019 update. Circulation 139(10), e56–e66 (2019).
  MedlineGoogle Scholar
• 2. Roth GA, Abate D, Abate KH et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. Lancet 392(10159), 1736–1788 (2018).
  MedlineGoogle Scholar
• 3. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 451(7181), 953–957 (2008).
  Medline CASGoogle Scholar
• 4. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 17(11), 1410–1422 (2011).
  Medline CASGoogle Scholar
• 5. Benjamin EJ, Virani SS, Callaway CW et al. Heart disease and stroke statistics-2018 update: a report from The American Heart Association. Circulation 137(12), e67–e492 (2018).
  MedlineGoogle Scholar
• 6. Costopoulos C, Brown AJ, Teng Z et al. Intravascular ultrasound and optical coherence tomography imaging of coronary atherosclerosis. Int. J. Cardiovasc. Imaging 32(1), 189–200 (2016).
  MedlineGoogle Scholar
• 7. Keraliya AR, Blankstein R. Regression of coronary atherosclerosis with medical therapy. N. Engl. J. Med. 376(14), 1370 (2017).
  MedlineGoogle Scholar
• 8. Conte MS, Pomposelli FB, Clair DG et al. Society for vascular surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J. Vasc. Surg. 61(3), S2–S41 (2015).
  Google Scholar
• 9. Shilov VV, Belevitin AB, Khubulava GG et al. Surgical treatment of patients with postinfarction aneurysm of the left ventricle in combination with atherosclerotic lesion of the lower extremity arteries. Vestn. Khir. Im. I. I. Grek. 166(5), 19–23 (2007).
  Medline CASGoogle Scholar
• 10. Cooper CJ, Murphy TP, Cutlip DE et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N. Engl. J. Med. 370(1), 13–22 (2014).
  Medline CASGoogle Scholar
• 11. Wu X, Wang G, Tang C et al. Mesenchymal stem cell seeding promotes reendothelialization of the endovascular stent. J. Biomed. Mater. Res. A 98A(3), 442–449 (2011).
  CASGoogle Scholar
• 12. Zhang Q, Shen Y, Tang C, Wu X, Yu Q, Wang G. Surface modification of coronary stents with SiCOH plasma nanocoatings for improving endothelialization and anticoagulation. J. Biomed. Mater. Res. B Appl. Biomater. 103(2), 464–472 (2015).
  MedlineGoogle Scholar
• 13. Wu X, Yin T, Tian J et al. Distinctive effects of CD34- and CD133-specific antibody-coated stents on re-endothelialization and in-stent restenosis at the early phase of vascular injury. Regen. Biomater. 2(2), 87–96 (2015).
  Medline CASGoogle Scholar
• 14. Sun D, Zheng Y, Yin T, Tang C, Yu Q, Wang G. Coronary drug-eluting stents: from design optimization to newer strategies. J. Biomed. Mater. Res. A 102(5), 1625–1640 (2014).
  MedlineGoogle Scholar
• 15. Zhao Y, Du R, Zhou T et al. Arsenic trioxide-coated stent is an endothelium-friendly drug eluting stent. Adv. Healthc. Mater. 7(15), 1800207 (2018).
  Google Scholar
• 16. Du R, Wang Y, Huang Y et al. Design and testing of hydrophobic core/hydrophilic shell nano/micro particles for drug-eluting stent coating. NPG Asia Mater. 10(7), 642–658 (2018).
  CASGoogle Scholar
• 17. Yang C, Yang J, Fu M et al. Cytotoxic effects of docetaxel as a candidate drug of drug-eluting stent on human umbilical vein endothelial cells and the signaling pathway of cell migration inhibition, adhesion delay and shape change. Regen. Biomater. 4(3), 167–178 (2017).
  MedlineGoogle Scholar
• 18. Hu T, Lin S, Du R et al. Design, preparation and performance of a novel drug-eluting stent with multiple layer coatings. Biomater. Sci. 5(9), 1845–1857 (2017).
  Medline CASGoogle Scholar
• 19. Hu T, Yang J, Cui K et al. Controlled slow-release drug-eluting stents for the prevention of coronary restenosis: Recent progress and future prospects. ACS Appl. Mater. Interfaces 7(22), 11695–11712 (2015).
  Medline CASGoogle Scholar
• 20. Malik N, Francis SE, Holt CM et al. Apoptosis and cell proliferation after porcine coronary angioplasty. Circulation 98(16), 1657–1665 (1998).
  Medline CASGoogle Scholar
• 21. Michos ED, Sibley CT, Baer J, Blaha MJ, Blumenthal RS. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (atherothrombosis intervention in metabolic syndrome with low HDL/High triglycerides: impact on global health outcomes) trial with previous surrogate endpoint trials. J. Am. Coll. Cardiol. 59(23), 2058–2064 (2012).
  Medline CASGoogle Scholar
• 22. Tian J, Gu X, Sun Y et al. Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc. Disord. 12(1), 70 (2012).
  Medline CASGoogle Scholar
• 23. Stroes ESG, Thompson PD, Corsini A et al. Statin-associated muscle symptoms: impact on statin therapy—European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur. Heart J. 36(17), 1012–1022 (2015).
  Medline CASGoogle Scholar
• 24. Martin SS, Blaha MJ, Blankstein R et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation 129(1), 77–86 (2014).
  Medline CASGoogle Scholar
• 25. Xu J, Yang W, Deng Q, Huang Q, Yang JE, Huang F. Flaxseed oil and α-lipoic acid combination reduces atherosclerosis risk factors in rats fed a high-fat diet. Lipids Health Dis. 11(1), 148 (2012).
  MedlineGoogle Scholar
• 26. Yi X, Xu L, Hiller S, Kim HS, Maeda N. Reduced α-lipoic acid synthase gene expression exacerbates atherosclerosis in diabetic apolipoprotein E-deficient mice. Atherosclerosis 223(1), 137–143 (2012).
  Medline CASGoogle Scholar
• 27. Shen D, Tian L, Shen T, Sun H, Liu P. α-lipoic acid protects human aortic endothelial cells against H₂O₂-induced injury and inhibits atherosclerosis in ovariectomized low density lipoprotein receptor knock-out mice. Cellular Physiol. Biochem. 47(6), 2261–2277 (2018).
  Medline CASGoogle Scholar
• 28. Peguero JG, Arenas IA, Lamas GA. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients. Trends Cardiovasc. Med. 24(6), 232–240 (2014).
  Medline CASGoogle Scholar
• 29. Lamas GA, Navasacien A, Mark DB, Lee KL. Heavy metals, cardiovascular disease, and the unexpected benefits of chelation therapy. J. Am. Coll. Cardiol. 67(20), 2411–2418 (2016).
  MedlineGoogle Scholar
• 30. Rathmann KL, Golightly LK. Chelation therapy of atherosclerosis. Ann. Pharmacother. 18(12), 1000–1003 (1984).
  CASGoogle Scholar
• 31. Karimi M, Zare H, Nik AB et al. Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine 11(5), 513–530 (2016).
  CASGoogle Scholar
• 32. Wang Y, Wang G. Polymeric nanomicelles: a potential hazard for the cardiovascular system? Nanomedicine 12(12), 1355–1358 (2017).
  CASGoogle Scholar
• 33. Fakruddin, Hossain Z, Afroz H. Prospects and applications of nanobiotechnology: a medical perspective. J. Nanobiotechnol. 10(1), 31 (2012).
  MedlineGoogle Scholar
• 34. Wu W, Ye C, Xiao H et al. Hierarchical mesoporous silica nanoparticles for tailorable drug release. Int. J. Pharm. 511(1), 65–72 (2016).
  Medline CASGoogle Scholar
• 35. Wu W, Wang W, Li J. Star polymers: advances in biomedical applications. Prog. Polym. Sci. 46, 55–85 (2015).
  CASGoogle Scholar
• 36. Li R-Q, Wu W, Song H-Q et al. Well-defined reducible cationic nanogels based on functionalized low-molecular-weight PGMA for effective pDNA and siRNA delivery. Acta Biomater. 41, 282–292 (2016).
  Medline CASGoogle Scholar
• 37. Cao S, Liu Y, Shang H et al. Supramolecular nanoparticles of calcitonin and dipeptide for long-term controlled release. J. Control. Release 256, 182–192 (2017).
  Medline CASGoogle Scholar
• 38. Yang X, Huang P, Wang H et al. Antibacterial and anti-biofouling coating on hydroxyapatite surface based on peptide-modified tannic acid. Colloids Surf. B. Biointerfaces 160, 136–143 (2017).
  Medline CASGoogle Scholar
• 39. Liu Y, Chen X, Li S et al. Calcitonin-loaded thermosensitive hydrogel for long-term antiosteopenia therapy. ACS Appl. Mater. Interfaces 9(28), 23428–23440 (2017).
  Medline CASGoogle Scholar
• 40. Bamrungsap S, Zhao Z, Chen T et al. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine 7(8), 1253–1271 (2012).
  CASGoogle Scholar
• 41. Barenholz Y. Doxil^®-The first FDA-approved nano-drug: lessons learned. J. Control. Release 160(2), 117–134 (2012).
  Medline CASGoogle Scholar
• 42. Crielaard BJ, Lammers T, Schiffelers RM, Storm G. Drug targeting systems for inflammatory disease: one for all, all for one. J. Control. Release 161(2), 225–234 (2012).
  Medline CASGoogle Scholar
• 43. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11(17–18), 812–818 (2006).
  Medline CASGoogle Scholar
• 44. Luo L, Wu W, Sun D et al. Acid-activated melittin for targeted and safe antitumor therapy. Bioconjug. Chem. 29(9), 2936–2944 (2018).
  Medline CASGoogle Scholar
• 45. Zhong Y, Wang Y, Luo L et al. Targeted polyethylenimine/(p53 plasmid) nanocomplexes for potential antitumor applications. Nanotechnology 30(14), 145601 (2019).
  Medline CASGoogle Scholar
• 46. Maeda H, Greish K, Fang J. The EPR effect and polymeric drugs: a paradigm shift for cancer chemotherapy in the 21st century. In: Polymer Therapeutics II. Satchi-Fainaro RDuncan R (Eds). Springer, Heidelberg, NY, 103–121 (2006).
  Google Scholar
• 47. England CG, Im H-J, Feng L et al. Re-assessing the enhanced permeability and retention effect in peripheral arterial disease using radiolabeled long circulating nanoparticles. Biomaterials 100, 101–109 (2016).
  Medline CASGoogle Scholar
• 48. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. In: Cancer Nanotechnology. Grobmyer SRMoudgil BM (Eds). Humana Press, NJ, USA, 25–37 (2010).
  Google Scholar
• 49. Wu W, Wang J, Lin Z, Li X, Li J. Tumor-acidity activated surface charge-conversion of polymeric nanocarriers for enhanced cell adhesion and targeted drug release. Macromol. Rapid Commun. 35(19), 1679–1684 (2014).
  Medline CASGoogle Scholar
• 50. Prabhakar U, Maeda H, Jain RK et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73(8), 2412–2417 (2013).
  Medline CASGoogle Scholar
• 51. Zhang K, Chen Y, Zhang T et al. A novel role of Id1 in regulating oscillatory shear stress-mediated lipid uptake in endothelial cells. Ann. Biomed. Eng. 46(6), 849–863 (2018).
  MedlineGoogle Scholar
• 52. Wei D, Chen Y, Tang C et al. LDL decreases the membrane compliance and cell adhesion of endothelial cells under fluid shear stress. Ann. Biomed. Eng. 41(3), 611–618 (2013).
  MedlineGoogle Scholar
• 53. Wang Y, Qiu J, Luo S et al. High shear stress induces atherosclerotic vulnerable plaque formation through angiogenesis. Regen. Biomater. 3(4), 257–267 (2016).
  MedlineGoogle Scholar
• 54. Qiu J, Lei D, Hu J et al. Effect of intraplaque angiogenesis to atherosclerotic rupture-prone plaque induced by high shear stress in rabbit model. Regen. Biomater. 4(4), 215–222 (2017).
  Medline CASGoogle Scholar
• 55. Xie X, Tan J, Wei D et al. In vitro and in vivo investigations on the effects of low-density lipoprotein concentration polarization and haemodynamics on atherosclerotic localization in rabbit and zebrafish. J. R. Soc. Interface 10(82), 20121053 (2013).
  MedlineGoogle Scholar
• 56. Chen T, Wu W, Xiao H, Chen Y, Chen M, Li J. Intelligent drug delivery system based on mesoporous silica nanoparticles coated with an ultra-pH-sensitive gatekeeper and poly(ethylene glycol). ACS Macro Lett. 5(1), 55–58 (2016).
  CASGoogle Scholar
• 57. Li S, Zhao Z, Wu W, Ding C, Li J. Dual pH-responsive micelles with both charge-conversional property and hydrophobic–hydrophilic transition for effective cellular uptake and intracellular drug release. Polym. Chem. 7(12), 2202–2208 (2016).
  CASGoogle Scholar
• 58. Wu W, Li S, Lin Z, Li J. pH-sensitive nanocarriers for enhanced tumor retention and rapid intracellular drug release. J. Control. Release 213, e111–e112 (2015).
  MedlineGoogle Scholar
• 59. Wu W, Chen M, Wang J et al. Nanocarriers with dual pH-sensitivity for enhanced tumor cell uptake and rapid intracellular drug release. RSC Adv. 4(58), 30780–30783 (2014).
  CASGoogle Scholar
• 60. Wu W, Luo L, Wang Y et al. Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications. Theranostics 8(11), 3038–3058 (2018).
  Medline CASGoogle Scholar
• 61. Li S, Wu W, Xiu K, Xu F, Li Z, Li J. Doxorubicin loaded pH-responsive micelles capable of rapid intracellular drug release for potential tumor therapy. J. Biomed. Nanotechnol. 10(8), 1480–1489 (2014).
  Medline CASGoogle Scholar
• 62. Shang H, Chen X, Liu Y, Yu L, Li J, Ding J. Cucurbit [7]-assisted sustained release of human calcitonin from thermosensitive block copolymer hydrogel. Int. J. Pharm. 527(1-2), 52–60 (2017).
  Medline CASGoogle Scholar
• 63. Xie J, Li A, Li J. Advances in pH-sensitive polymers for smart insulin delivery. Macromol. Rapid Commun. 38(23), 1700413 (2017).
  Google Scholar
• 64. Blum AP, Kammeyer JK, Rush AM, Callmann CE, Hahn ME, Gianneschi NC. Stimuli-responsive nanomaterials for biomedical applications. J. Am. Chem. Soc. 137(6), 2140–2154 (2015).
  Medline CASGoogle Scholar
• 65. Fernandes DC, Araujo TL, Laurindo FR, Tanaka LY. Chapter 7 - Hemodynamic forces in the endothelium: from mechanotransduction to implications on development of atherosclerosis. In: Endothelium and Cardiovascular Diseases. Da Luz PLLibby PChagas ACPLaurindo FRM (Eds). Academic Press, London, UK, 85–95 (2018).
  Google Scholar
• 66. Da Luz PL, Chagas ACP, Dourado PMM, Laurindo FR. Chapter 33 - Endothelium in atherosclerosis: plaque formation and its complications. In: Endothelium and Cardiovascular Diseases. Da Luz PLLibby PChagas ACPLaurindo FRM (Eds). Academic Press, London, UK, 493–512 (2018).
  Google Scholar
• 67. Mccarty OJT, Conley RB, Shentu W et al. Molecular imaging of activated von willebrand factor to detect high-risk atherosclerotic phenotype. JACC Cardiovasc. Imaging 3(9), 947–955 (2010).
  MedlineGoogle Scholar
• 68. Yoo D, Lee J-H, Shin T-H, Cheon J. Theranostic magnetic nanoparticles. Acc. Chem. Res. 44(10), 863–874 (2011).
  Medline CASGoogle Scholar
• 69. Wootton DM, Alevriadou BR. The shear stress of busting blood clots. N. Engl. J. Med. 367(14), 1361–1363 (2012).
  Medline CASGoogle Scholar
• 70. Saxer T, Zumbuehl A, Muller B. The use of shear stress for targeted drug delivery. Cardiovasc. Res. 99(2), 328–333 (2013).
  Medline CASGoogle Scholar
• 71. Westein E, Flierl U, Hagemeyer CE, Peter K. Destination known: targeted drug delivery in atherosclerosis and thrombosis. Drug Dev. Res. 74(7), 460–471 (2013).
  CASGoogle Scholar
• 72. Schiener M, Hossann M, Viola JR et al. Nanomedicine-based strategies for treatment of atherosclerosis. Trends Cardiovasc. Med. 20(5), 271–281 (2014).
  CASGoogle Scholar
• 73. Cicha I. Strategies to enhance nanoparticle-endothelial interactions under flow. J. Cell. Biotechnol. 1(2), 191–208 (2016).
  Google Scholar
• 74. Xia Y, Shi C-Y, Xiong W, Hou X-L, Fang J-G, Wang W-Q. Shear stress-sensitive carriers for localized drug delivery. Curr. Pharm. Des. 22(38), 5855–5867 (2016).
  Medline CASGoogle Scholar
• 75. Kelley WJ, Safari H, Lopezcazares G, Eniolaadefeso O. Vascular-targeted nanocarriers: design considerations and strategies for successful treatment of atherosclerosis and other vascular diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8(6), 909–926 (2016).
  MedlineGoogle Scholar
• 76. Epshtein M, Korin N. Shear targeted drug delivery to stenotic blood vessels. J. Biomech. 50, 217–221 (2017).
  MedlineGoogle Scholar
• 77. Calin M, Manduteanu I. Emerging nanocarriers-based approaches to diagnose and reduce vascular inflammation in atherosclerosis. Curr. Med. Chem. 24(6), 550–567 (2017).
  Medline CASGoogle Scholar
• 78. Bejarano J, Navarro-Marquez M, Morales-Zavala F et al. Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Theranostics 8(17), 4710 (2018).
  Medline CASGoogle Scholar
• 79. Gupta P, Garcia E, Sarkar A et al. Nanoparticle based treatment for cardiovascular diseases. Cardiovasc. Hematol. Disord. Drug Targets 19(1), 33–44 (2019).
  Medline CASGoogle Scholar
• 80. Nakhlband A, Eskandani M, Omidi Y et al. Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective. Bioimpacts 8(1), 59–75 (2018).
  Medline CASGoogle Scholar
• 81. Maruf A, Wang Y, Yin T et al. Atherosclerosis treatment with stimuli-responsive nanoagents: recent advances and future perspectives. Adv. Healthc. Mater. 8(11), 1900036 (2019). •• Recent comprehensive stimuli-responsive review in atherosclerosis.
  Google Scholar
• 82. Wang J, Kaplan JA, Colson YL, Grinstaff MW. Mechanoresponsive materials for drug delivery: harnessing forces for controlled release. Adv. Drug. Deliv. Rev. 108, 68–82 (2017).
  Medline CASGoogle Scholar
• 83. Zhang Y, Yu J, Bomba HN, Zhu Y, Gu Z. Mechanical force-triggered drug delivery. Chem. Rev. 116(19), 12536–12563 (2016).
  Medline CASGoogle Scholar
• 84. Korin N. Mechanoresponsive nanotherapeutic for localized drug delivery to flow obstructed blood vessels. Ther. Deliv. 6(8), 895–897 (2015).
  Medline CASGoogle Scholar
• 85. Santos LJ, Reis RL, Gomes ME. Harnessing magnetic-mechano actuation in regenerative medicine and tissue engineering. Trends Biotechnol. 33(8), 471–479 (2015).
  Medline CASGoogle Scholar
• 86. Golovin YI, Gribanovsky SL, Golovin DY et al. Towards nanomedicines of the future: remote magneto-mechanical actuation of nanomedicines by alternating magnetic fields. J. Control. Release 219, 43–60 (2015).
  Medline CASGoogle Scholar
• 87. Weder C. Mechanoresponsive materials. J. Mater. Chem. 21(23), 8235–8236 (2011).
  CASGoogle Scholar
• 88. Korin N, Kanapathipillai M, Matthews BD et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 337(6095), 738–742 (2012).
  Medline CASGoogle Scholar
• 89. Farokhzad OC, Khademhosseini A, Jon S et al. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal. Chem. 77(17), 5453–5459 (2005).
  Medline CASGoogle Scholar
• 90. Korin N, Kanapathipillai M, Ingber DE. Shear-responsive platelet mimetics for targeted drug delivery. Isr. J. Chem. 53(9–10), 610–615 (2013). • First development of shear-responsive nanoplatforms (NPs).
  CASGoogle Scholar
• 91. Zha L, Banik B, Alexis F. Stimulus responsive nanogels for drug delivery. Soft Matt. 7(13), 5908–5916 (2011).
  CASGoogle Scholar
• 92. Cecchi E, Giglioli C, Valente S et al. Role of hemodynamic shear stress in cardiovascular disease. Atherosclerosis 214(2), 249–256 (2011).
  Medline CASGoogle Scholar
• 93. Reneman RS, Hoeks APG. Wall shear stress as measured in vivo: consequences for the design of the arterial system. Med. Biol. Eng. Comput. 46(5), 499–507 (2008).
  MedlineGoogle Scholar
• 94. Dai Q, Nelson A. Magnetically-responsive self assembled composites. Chem. Soc. Rev. 39(11), 4057–4066 (2010).
  Medline CASGoogle Scholar
• 95. Kanwar RK, Chaudhary R, Tsuzuki T, Kanwar JR. Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis: how far have we come? Nanomedicine 7(6), 899–916 (2012).
  CASGoogle Scholar
• 96. Usman A, Sadat U, Patterson AJ et al. Use of ultrasmall superparamagnetic iron oxide particles for imaging carotid atherosclerosis. Nanomedicine 10(19), 3077–3087 (2015).
  CASGoogle Scholar
• 97. Qin H, Zhou T, Yang S, Chen Q, Xing D. Gadolinium(III)-gold nanorods for MRI and photoacoustic imaging dual-modality detection of macrophages in atherosclerotic inflammation. Nanomedicine 8(10), 1611–1624 (2013).
  CASGoogle Scholar
• 98. Zrinyi M, Barsi L, Buki A. Deformation of ferrogels induced by nonuniform magnetic fields. J. Chem. Phys. 104(21), 8750–8756 (1996).
  CASGoogle Scholar
• 99. Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opin. Drug Deliv. 6(1), 53–70 (2009).
  Medline CASGoogle Scholar
• 100. Sensenig R, Sapir Y, Macdonald C, Cohen S, Polyak B. Magnetic nanoparticle-based approaches to locally target therapy and enhance tissue regeneration in vivo. Nanomedicine 7(9), 1425–1442 (2012).
  CASGoogle Scholar
• 101. Zhao Y-Z, Du L-N, Lu C-T, Jin Y-G, Ge S-P. Potential and problems in ultrasound-responsive drug delivery systems. Int. J. Nanomedicine 8, 1621–1633 (2013).
  MedlineGoogle Scholar
• 102. Wang K, Guo B, Zhang F et al. Design of ligands-conjuncted lipid nanobubbles as ultrasound contrast agents targeted to atherosclerotic plaques. J. Nanosci. Nanotechnol. 16(7), 7611–7616 (2016).
  CASGoogle Scholar
• 103. Lammertink BHA, Bos C, Deckers R, Storm G, Moonen CTW, Escoffre J. Sonochemotherapy: from bench to bedside. Front. Pharmacol. 6, 138 (2015).
  MedlineGoogle Scholar
• 104. Carovac A, Smajlovic F, Junuzovic D. Application of ultrasound in medicine. Acta Inform. Med. 19(3), 168–171 (2011).
  MedlineGoogle Scholar
• 105. Wang H-K, Chou Y-H, Chiou H-J, Chiou S-Y, Chang C-Y. B-flow ultrasonography of peripheral vascular diseases. J. Med. Ultrasound 13(4), 186–195 (2005).
  CASGoogle Scholar
• 106. Wachsberg RH. B-flow imaging of the hepatic vasculature: correlation with color doppler sonography. AJR Am. J. Roentgenol. 188(6), W522–W533 (2007).
  MedlineGoogle Scholar
• 107. Cobbold RS. Pulsed methods for flow velocity estimation and imaging. In: Foundations of biomedical ultrasound. Oxford University Press, NY, USA, 652–673 (2007).
  Google Scholar
• 108. Wan G, Liu Y, Chen B, Liu Y, Wang Y, Zhang N. Recent advances of sonodynamic therapy in cancer treatment. Cancer Biol. Med. 13(3), 325–338 (2016).
  Medline CASGoogle Scholar
• 109. Olson ES, Jiang T, Aguilera TA et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl Acad. Sci. USA 107(9), 4311–4316 (2010).
  Medline CASGoogle Scholar
• 110. Rink JS, Sun W, Misener S et al. Nitric oxide-delivering high-density lipoprotein-like nanoparticles as a biomimetic nanotherapy for vascular diseases. ACS Appl. Mater. Interfaces 10(8), 6904–6916 (2018).
  Medline CASGoogle Scholar
• 111. Loerakker S, Stassen OMJA, Huurne FMT, Boareto M, Bouten CVC, Sahlgren CM. Mechanosensitivity of Jagged–Notch signaling can induce a switch-type behavior in vascular homeostasis. Proc. Natl Acad. Sci. USA 115(16), E3682–E3691 (2018).
  Medline CASGoogle Scholar
• 112. Yan F, Sun Y, Mao Y et al. Ultrasound molecular imaging of atherosclerosis for early diagnosis and therapeutic evaluation through leucocyte-like multiple targeted microbubbles. Theranostics 8(7), 1879–1891 (2018).
  Medline CASGoogle Scholar
• 113. Hossaini Nasr S, Tonson A, El-Dakdouki MH et al. Effects of nanoprobe morphology on cellular binding and inflammatory responses: hyaluronan-conjugated magnetic nanoworms for magnetic resonance imaging of atherosclerotic plaques. ACS Appl. Mater. Interfaces 10(14), 11495–11507 (2018).
  MedlineGoogle Scholar
• 114. Jacobinvalat M, Larochetraineau J, Lariviere M et al. Nanoparticles functionalised with an anti-platelet human antibody for in vivo detection of atherosclerotic plaque by magnetic resonance imaging. Nanomedicine 11(4), 927–937 (2015).
  Medline CASGoogle Scholar
• 115. Kamat MN, Elboubbou K, Zhu DC et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug. Chem. 21(11), 2128–2135 (2010).
  Medline CASGoogle Scholar
• 116. Kim M, Sahu A, Kim GB et al. Comparison of in vivo targeting ability between cRGD and collagen-targeting peptide conjugated nano-carriers for atherosclerosis. J. Control. Release 269, 337–346 (2018).
  Medline CASGoogle Scholar
• 117. Khodabandehlou K, Masehilano JJ, Poon C, Wang JL, Chung EJ. Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis. Exp. Biol. Med. 242(8), 799–812 (2017).
  CASGoogle Scholar
• 118. Nahrendorf M, Zhang H, Hembrador S et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117(3), 379–387 (2008).
  Medline CASGoogle Scholar
• 119. Ding J, Wang Y, Ma M et al. CT/fluorescence dual-modal nanoemulsion platform for investigating atherosclerotic plaques. Biomaterials 34(1), 209–216 (2013).
  Medline CASGoogle Scholar
• 120. Eldakdouki MH, Elboubbou K, Kamat MN et al. CD44 targeting magnetic glyconanoparticles for atherosclerotic plaque imaging. Pharm. Res. 31(6), 1426–1437 (2014).
  Medline CASGoogle Scholar
• 121. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5(3), 161–171 (2005).
  Medline CASGoogle Scholar
• 122. Patil VRS, Campbell CJ, Yun YH, Slack SM, Goetz DJ. Particle diameter influences adhesion under flow. Biophys. J. 80(4), 1733–1743 (2001).
  MedlineGoogle Scholar
• 123. Stolnik S, Illum L, Davis S. Long circulating microparticulate drug carriers. Adv. Drug. Deliv. Rev. 64, 290–301 (2012).
  Google Scholar
• 124. Ilium L, Davis S, Wilson C, Thomas N, Frier M, Hardy J. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int. J. Pharm. 12(2–3), 135–146 (1982).
  Google Scholar
• 125. Panyam J, Dali MM, Sahoo SK et al. Polymer degradation and in vitro release of a model protein from poly (D,L-lactide-co-glycolide) nano-and microparticles. J. Control. Release 92(1–2), 173–187 (2003).
  Medline CASGoogle Scholar
• 126. Dunne M, Corrigan O, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 21(16), 1659–1668 (2000).
  Medline CASGoogle Scholar
• 127. Holme MN, Fedotenko I, Abegg D et al. Shear-stress sensitive lenticular vesicles for targeted drug delivery. Nat. Nanotechnol. 7(8), 536–543 (2012). • The application of shear-responsive NPs in atherosclerosis management.
  Medline CASGoogle Scholar
• 128. Molloy CP, Yao Y, Kammoun H et al. Shear-sensitive nanocapsules drug release for site-specific inhibition of occlusive thrombus formation. J. Thromb. Haemost. 15(5), 972–982 (2017).
  Medline CASGoogle Scholar
• 129. Griffin MT, Zhu Y, Liu Z, Aidun CK, Ku DN. Inhibition of high shear arterial thrombosis by charged nanoparticles. Biomicrofluidics 12(4), 042210 (2018).
  MedlineGoogle Scholar
• 130. Chen C, Li S, Liu K, Ma G, Yan X. Co-assembly of heparin and polypeptide hybrid nanoparticles for biomimetic delivery and anti-thrombus therapy. Small 12(34), 4719–4725 (2016).
  Medline CASGoogle Scholar
• 131. Jin R, Lin B, Li D, Ai H. Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: design considerations and clinical applications. Curr. Opin. Pharmacol. 18, 18–27 (2014).
  Medline CASGoogle Scholar
• 132. Merkel TJ, Herlihy KP, Nunes JK, Orgel R, Rolland JP, Desimone JM. Scalable, shape-specific, top-down fabrication methods for the synthesis of engineered colloidal particles. Langmuir 26(16), 13086–13096 (2010).
  Medline CASGoogle Scholar
• 133. Tsuzuki T, Mccormick PG. Mechanochemical synthesis of nanoparticles. J. Mater. Sci. 39, 5143–5146 (2004).
  CASGoogle Scholar
• 134. Liong M, Lu J, Kovochich M et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2(5), 889–896 (2008).
  Medline CASGoogle Scholar
• 135. Amendola V, Meneghetti M. Laser ablation synthesis in solution and size manipulation of noble metal nanoparticles. Phys. Chem. Chem. Phys. 11(20), 3805–3821 (2009).
  Medline CASGoogle Scholar
• 136. Hudson R, Feng Y, Varma RS, Moores A. Bare magnetic nanoparticles: sustainable synthesis and applications in catalytic organic transformations. Green Chem. 16(10), 4493–4505 (2014).
  CASGoogle Scholar
• 137. Laurent S, Forge D, Port M et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 108(6), 2064–2110 (2008).
  Medline CASGoogle Scholar
• 138. Mosayebi J, Kiyasatfar M, Laurent S. Synthesis, functionalization, and design of magnetic nanoparticles for theranostic applications. Adv. Healthc. Mater. 6(23), 1700306 (2017).
  Google Scholar
• 139. Stride EP, Coussios CC. Cavitation and contrast: The use of bubbles in ultrasound imaging and therapy. Proc. Inst. Mech. Eng. H. 224(2), 171–191 (2010).
  Medline CASGoogle Scholar
• 140. Bailey MR, Khokhlova VA, Sapozhnikov OA, Kargl SG, Crum LA. Physical mechanisms of the therapeutic effect of ultrasound (a review). Acoust. Phys. 49(4), 369–388 (2003).
  Google Scholar
• 141. Prajapati JV, Agrawal YK. Synthesis, characterization and application of microbubbles: a review. Int. J. Pharm. Sci. Res. 3(6), 1532–1543 (2012).
  CASGoogle Scholar
• 142. Zhou M, Cavalieri F, Caruso F, Ashokkumar M. Confinement of acoustic cavitation for the synthesis of protein-shelled nanobubbles for diagnostics and nucleic acid delivery. ACS Macro Lett. 1(7), 853–856 (2012). •• One of the fabrication method of microbubbles, providing a promising way to develop microbubbles.
  CASGoogle Scholar
• 143. Wang Y, Zhang K, Qin X et al. Biomimetic nanotherapies: red blood cell based core-shell structured nanocomplexes for atherosclerosis management. Adv. Sci. 6(12), 1900172 (2019). •• Recent development of nanocomplex for atherosclerosis management.
  Google Scholar
• 144. Song Y, Huang Z, Liu X et al. Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE^−/−) mice. Nanomedicine 15(1), 13–24 (2019).
  Medline CASGoogle Scholar
• 145. Kunkun W, Binbin G, Feng Z et al. Design of ligands-conjuncted lipid nanobubbles as ultrasound contrast agents targeted to atherosclerotic plaques. J. Nanosci. Nanotechnol. 16(7), 7611–7616 (2016).
  Google Scholar
• 146. Yuan H, Hu H, Sun J et al. Ultrasound microbubble delivery targeting intraplaque neovascularization inhibits atherosclerotic plaque in an ApoE-deficient mouse model. In Vivo 32(5), 1025–1032 (2018).
  Medline CASGoogle Scholar
• 147. Ji R, Li X, Zhou C et al. Identifying macrophage enrichment in atherosclerotic plaques by targeting dual-modal US imaging/MRI based on biodegradable Fe-doped hollow silica nanospheres conjugated with anti-CD68 antibody. Nanoscale 10(43), 20246–20255 (2018).
  Medline CASGoogle Scholar
• 148. Hamzah J, Kotamraju VR, Seo JW et al. Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc. Natl Acad. Sci. USA 108(17), 7154–7159 (2011).
  Medline CASGoogle Scholar
• 149. Cormode DP, Brileysaebo KC, Mulder WJM et al. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 4(9), 1437–1444 (2008).
  Medline CASGoogle Scholar
• 150. Zhang L, Tian XY, Chan CKW et al. Promoting the delivery of nanoparticles to atherosclerotic plaques by DNA coating. ACS Appl. Mater. Interfaces 11(15), 13888–13904 (2018). • The application of magnetic-responsive NPs in atherosclerosis management.
  MedlineGoogle Scholar
• 151. Matuszak J, Lutz B, Sekita A et al. Drug delivery to atherosclerotic plaques using superparamagnetic iron oxide nanoparticles. Int. J. Nanomedicine 13, 8443–8460 (2018).
  Medline CASGoogle Scholar
• 152. Cicha I, Matuszak J, Lutz B, Alexiou C, Lyer S. P3781 Magnetic drug targeting to vascular injury regions and atherosclerotic lesions: in vivo pilot study. Eur. Heart J. 39(Suppl. 1), 3781 (2018).
  Google Scholar
• 153. Zhang X, Zhao K, Wang J et al. Design of simvastatin-loaded polymeric microbubbles as targeted ultrasound contrast agents for vascular imaging and drug delivery in the identification of atherosclerotic plaque. New J. Chem. 40(2), 1256–1262 (2016).
  CASGoogle Scholar
• 154. Wong WT, Ma S, Tian XY, Gonzalez AB, Ebong EE, Shen H. Targeted delivery of shear stress-inducible micrornas by nanoparticles to prevent vulnerable atherosclerotic lesions. Methodist Debakey Cardiovasc. J. 12(3), 152–156 (2016).
  MedlineGoogle Scholar
• 155. Petrov L, Kaikkonen MU, Heikura T et al. Ultrasound and micro-bubbles coated with anti-VCAM-1 antibody for selective gene delivery to unstable atherosclerotic plaques in mouse aorta post angioplasty. Cardiovasc. Gene Ther. 16, s55–s56 (2008).
  Google Scholar
• 156. Noukeu LC, Wolf J, Yuan B, Banerjee S, Nguyen KT. Nanoparticles for detection and treatment of peripheral arterial disease. Small 14(32), 1800644 (2018).
  Google Scholar
• 157. Dong Y, Chen H, Chen C et al. Polymer-lipid hybrid theranostic nanoparticles co-delivering ultrasmall superparamagnetic iron oxide and paclitaxel for targeted magnetic resonance imaging and therapy in atherosclerotic plaque. J. Biomed. Nanotechnol. 12(6), 1245–1257 (2016).
  Medline CASGoogle Scholar
• 158. Pont I, Calatayudpascual A, Lopezcastellano A et al. Anti-angiogenic drug loaded liposomes: nanotherapy for early atherosclerotic lesions in mice. PLoS ONE 13(1), e0190540 (2018).
  MedlineGoogle Scholar
• 159. Tachibana K, Feril LB, Ikeda-Dantsuji Y. Sonodynamic therapy. Ultrasonics 48(4), 253–259 (2008).
  Medline CASGoogle Scholar
• 160. Geng C, Zhang Y, Hidru TH et al. Sonodynamic therapy: a potential treatment for atherosclerosis. Life Sci. 207, 304–313 (2018).
  Medline CASGoogle Scholar
• 161. Wang Y, Wang W, Xu H et al. Non-lethal sonodynamic therapy inhibits atherosclerotic plaque progression in ApoE^-/- mice and attenuates Ox-LDL-mediated macrophage impairment by inducing heme oxygenase-1. Cell. Physiol. Biochem. 41(6), 2432–2446 (2017). • The application of ultrasound-responsive NPs in atherosclerosis management.
  Medline CASGoogle Scholar